Format

Send to:

Choose Destination
See comment in PubMed Commons below
Vaccine. 2010 Aug 31;28(38):6333-7. doi: 10.1016/j.vaccine.2010.06.093. Epub 2010 Jul 14.

Vaccination with a chaperone complex based on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor growth in mice.

Author information

  • 1Department of Urology, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing 400042, China.

Abstract

Increasing knowledge demonstrate that prostate stem cell antigen (PSCA) is a promising candidate for immunotherapy of advanced prostate cancer. However, tumor escape with down-regulation of target antigens may limit the susceptibility of tumor cells to the immune attack. Concomitant generation of T-cell responses against several immunodominant antigens may circumvent this potential drawback. In this study, we prepared the chaperone complex vaccine based on PSCA and GRP170, and utilized it to immunize the C57BL/6 mice. In addition, the T-cell response was monitored with ELISPOT and (51)Cr-release assays, and the tumor growth and the life span of tumor-bearing mice were assessed. The results demonstrated the chaperone complex based on PSCA and GRP170 could enhance the T-cell mediate immune responses, which significantly inhibited the tumor growth and prolonged the life span of tumor-bearing mice. In conclusion, our findings supported the strategy of chaperone complex, based on PSCA and GRP170, could be an effective treatment for prostate cancer therapy.

(c) 2010. Published by Elsevier Ltd.

PMID:
20637304
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk